Drug data last refreshed 2d ago · AI intelligence enriched 2w ago
INDERIDE LA 80/50 is a fixed-dose combination of propranolol hydrochloride (a non-selective beta-blocker) and hydrochlorothiazide (a thiazide diuretic) in extended-release capsule form. It is indicated for the management of hypertension, combining two complementary antihypertensive mechanisms to reduce blood pressure through beta-adrenergic blockade and diuresis. This combination therapy targets patients requiring dual-agent control.
Product faces loss-of-exclusivity headwinds with moderate competitive pressure (30), indicating a mature asset likely managed by a lean team focused on retention rather than growth.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on INDERIDE LA offers limited growth trajectory as the product approaches loss of exclusivity with zero linked job openings. Career advancement on this asset is constrained; professionals should view it as a stability role or as a stepping stone to growth-stage products.
Worked on INDERIDE LA 80/50 at Thayer Medical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.